论文部分内容阅读
为了观察培美曲塞联合顺铂治疗晚期(ⅢB～Ⅳ)期肺腺癌的疗效及毒副反应,选取32例晚期肺腺癌患者,应用培美曲塞500mg/m2,静脉滴入15min,d1;顺铂75mg/m2,静脉滴入,d1(培美曲塞后),21d为1个周期,至少2个周期评价疗效。32例患者均可评价疗效,CR1例,PR 10例,SD10例,PD11例,总有效率(CR+PR)为34.3%。所有患者中位疾病进展时间(TTP)为5.8个月(1.2～9.8个月),中位生存时间(OS)为12.1个月(3.8～26.5个月)。主要毒副反应为胃肠道反应65.6%,多为Ⅰ～Ⅱ度;白细胞减少41.2%,多为Ⅰ～Ⅱ度。初步研究结果提示,培美曲塞联合顺铂治疗晚期肺腺癌疗效较好,不良反应小,安全性高。
In order to observe the efficacy and toxicity of pemetrexed combined with cisplatin in the treatment of advanced stage lung cancer (ⅢB-Ⅳ), 32 patients with advanced lung adenocarcinoma were selected and treated with pemetrexed 500mg / m2 for 15 minutes, d1; cisplatin 75mg / m2, intravenous infusion, d1 (pemetrexed), 21d for a cycle, at least 2 cycles evaluation of efficacy. Efficacy was evaluated in 32 patients, CR1, PR 10, SD10 and PD11, the total effective rate (CR + PR) was 34.3%. All patients had a median time to disease progression (TTP) of 5.8 months (range 1.2 to 9.8 months) and a median duration of survival (OS) of 12.1 months (3.8 to 26.5 months). The main side effects of gastrointestinal reactions 65.6%, mostly Ⅰ ~ Ⅱ degrees; leukopenia 41.2%, mostly Ⅰ ~ Ⅱ degrees. Preliminary results suggest that pemetrexed combined with cisplatin in the treatment of advanced lung adenocarcinoma better efficacy, adverse reactions, high safety.